Clinical trials: Asthmatic Patients
Asthma
A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional participant reported sleep outcomes To evaluate the effect of dupilumab on objective sleep…
- Trial name
- MORPHEO (NCT04502862)
- Testing
- SAR231893
- Where
- 55 sites in United States, Argentina and 9 more
- Volunteers
- 202 people
- Sponsor
- Sanofi
Allergic Asthma
Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)
The primary purpose of this study is to examine whether the geometric mean of serum free IgE level at 24 weeks of the treatment period in Japanese pediatric patients (6 to 15 years of age) reaches under 25 ng/mL (target level).
- Trial name
- NCT01155700
- Testing
- omalizumab
- Where
- 17 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study of MK0359 in Patients With Chronic Asthma (0359-013)
A study to test the effect of MK0359 in lessening the symptoms of asthma as compared to placebo.
- Trial name
- NCT00482898
- Testing
- MK0359
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China
The primary objective of the NIS is to evaluate the severity of newly diagnosed asthma patients based on Global Initiative for Asthma (GINA) severity category (GINA 2006 update).
- Trial name
- INITIAL (NCT02143739)
- Where
- 30 sites in China
- Volunteers
- 4,817 people
- Sponsor
- AstraZeneca
Asthma
A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)
A study to determine the efficacy of MK0476 in the Treatment of Asthmatic Patients Aged 2 to 5 Years.
- Trial name
- NCT00700661
- Testing
- montelukast
- Volunteers
- 500 people
- Sponsor
- Organon and Co
Asthma
The Importance of Tailored Education And Device Handling for Asthmatic Patients
Significant advancements have been made in asthma medication over the past decades. Highly effective treatments are available for patients; however, both adherence and proper device usage remain below the desired levels, based on…
- Trial name
- TEACH (NCT06840522)
- Where
- 6 sites in Hungary
- Volunteers
- 250 people
- Sponsor
- Chiesi Hungary Ltd.
Asthma
Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices
The purpose of this study is to evaluate, at steady-state, the systemic exposure and the lung deposition of B17MP (active metabolite of BDP) as AUC0-12h,ss and Cmax,ss, after inhalation of BDP (Clenil® Modulite®) with the…
- Trial name
- NCT01370031
- Testing
- Clenil® Modulite® via AeroChamber Plus™, Clenil® Modulite® via Volumatic™ spacer, Clenil® Modulite® via AeroChamber Plus™ plus charcoal block
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Severe Asthma
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
This study is an observational multicenter cross-sectional study. Planned study population consists of 5 000 adult patients with uncontrolled SA receiving treatment according to standard of care (except biologics).
- Trial name
- CORSAR (NCT06472310)
- Where
- 40 sites in Russia
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
COPD, Asthma
Cardiorespiratory Diagnostic Study
This study uses a new breathing device called 'N-Tidal C' handset which measures breathing patterns. Investigators have found that people with cardiac and respiratory illnesses breathe out a gas, called carbon dioxide (CO2), in a…
- Conditions
- COPD, Asthma, Lung Cancer, Anemia
- Trial name
- CARES (NCT04939558)
- Testing
- N-Tidal C handset
- Where
- United Kingdom
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- TidalSense
Asthma
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of two medications in one inhaler.
- Trial name
- NCT00649025
- Testing
- FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA
- Where
- 103 sites in United States, Argentina and 8 more
- Volunteers
- 438 people
- Sponsor
- SkyePharma AG
Asthma
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma.
- Trial name
- NCT00467740
- Testing
- BI 1744 CL
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma.
- Trial name
- NCT04203797
- Testing
- dupilumab
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Regeneron Pharmaceuticals
Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic
Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract of Phleum pratense in the rhinoconjunctivitis and/or asthma of slight or moderate…
- Conditions
- Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic, Asthma
- Trial name
- NCT00501527
- Testing
- Immunotherapy with modified extract of P. pratense pollen
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Laboratorios Leti, S.L.
Asthma
Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma
The aim of the study is to evaluate, comparatively to a placebo, the activity of oral AB1010, administered at three dose levels during 4 months to patients with severe persistent corticosteroid dependent asthma, assessed on : the…
- Trial name
- NCT00842270
- Testing
- AB1010
- Volunteers
- 44 people
- Sponsor
- AB Science
Rhinitis, Allergic, Rhinoconjunctivitis, Allergic
HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human
The aim of this first-in-human phase I study is to assess the safety and tolerability of HAL-MRE1 subcutaneous immunotherapy in subjects suffering from ragweed pollen-induced allergic rhinitis/rhinoconjunctivitis with or without…
- Trial name
- NCT03758456
- Testing
- HAL-MRE1
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- HAL Allergy
Asthma
Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on medium doses of ICS-LABA.
- Trial name
- NCT01947946
- Testing
- Benralizumab
- Where
- 47 sites in United States, Argentina and 5 more
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Bronchial Asthma
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
This patient follow-up programme was designed to describe the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy in routine clinical practice in comparison with the already documented use…
- Trial name
- NCT00505388
- Where
- 695 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 5,137 people
- Sponsor
- AstraZeneca
Asthma
Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients
The objective of this study is to assess the efficacy and safety of SOTB07 in asthma patients by observing changes FEV1 (% predicted) as the primary efficacy endpoint after oral administration of SOTB07 200mg, 400mg, placebo for…
- Trial name
- NCT01907763
- Testing
- SOTB07 200mg, SOTB07 400mg
- Where
- South Korea
- Volunteers
- 194 people
- Sponsor
- SK Chemicals Co., Ltd.
Asthma
Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)
Primary objective The primary objective was to evaluate the superiority of CHF 5259 (glycopyrronium bromide [GB]) in a pressurised metered dose inhaler (pMDI) (50 μg total daily dose) versus placebo in terms of forced expiratory…
- Trial name
- ELITRA (NCT02296411)
- Testing
- CHF 5259 12.5 µg + Qvar
- Where
- 28 sites in Bulgaria, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Allergic Bronchopulmonary Aspergillosis
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic…
- Trial name
- NCT03960606
- Testing
- PUR1900
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 7 people
- Sponsor
- Pulmatrix Inc.